Among the TKIs used in CML, ponatinib is a third generation BCR::ABL1 TKI designed to overcome TKI resistance caused by T315I mutation in BCR::ABL1. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.